Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

26.66 -0.01 (-0.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,634,083
Open 26.67
Bid (Size) 26.64 (500)
Ask (Size) 26.68 (400)
Prev. Close 26.67
Today's Range 26.64 - 26.69
52wk Range 9.830 - 26.76
Shares Outstanding 34,233,643
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unusual volume stocks are being observed in Thursday's session. ↗
Via Chartmill
News headline image
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement ↗
On April 29, 2026, a rare-disease deal reshapes biotech M&A expectations as investors weigh tender terms. 
Via The Motley Fool
Topics Stocks

Performance

YTD
+72.4%
+72.4%
1 Month
+32.4%
+32.4%
3 Month
+70.4%
+70.4%
6 Month
+143.0%
+143.0%
1 Year
+93.6%
+93.6%

More News

Read More
Wednesday's session: top gainers and losers ↗
Via Chartmill
Which stocks are moving on Wednesday? ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart ↗
Via Stocktwits
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is KalVista Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, KalVista Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does KalVista Pharmaceuticals, Inc. - Common Stock trade on?
KalVista Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock is KALV on the Nasdaq Stock Market
What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?
The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 26.66
When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 04/30/26 04:00 PM ET
What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?
The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 912.67M
How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?
KalVista Pharmaceuticals, Inc. - Common Stock has 913M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.